BestPractice Nordic Finland

22/12/2020

Did you miss the highlights from San Antonio Breast Cancer Symposium 2020? - One of the them were the data from KEYNOTE - 355 presented by Hope S. Rugo, MD, Professor of Medicine fra University of California San Francisco. The results from the study, where triple negative breast cancer patients, were treated with a combination of pembrolizumab plus chemotherapy, were convincing enough to grant the treatment accelerated FDA approval. Log in and get all the highlights from San Antonio Breast Cancer Symposium.

In this MEDtalk, Hope S. Rugo, MD, Professor of Medicine, University of California San Francisco, present data from KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer.

14/12/2020

SABCS2020: Trastuzumab Deruxtecan Continues to Demonstrate Durable Responses in HER2 Positive Metastatic Breast Cancer
In this MEDtalk Fabrice André, Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France presents the key clinical messages from DESTINY-Breast01 study

In this MEDtalk Fabrice André, Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France presents the key clinical messages from DESTINY-Breast01 study

09/12/2020

In this multi-centre open-label phase Ib-II trial the safety and efficacy of treatment of relapse/refractory Mantle Cell Lymfoma with Venetoclax, Lenalidomide and Rituximab was evaluated. In this MEDtalk Mats Jerkeman, MD, Ph.D., Department of Oncology, Lund University and Skåne University Hospital, Lund, Sweden present the study and the interesting response adapted treatment strategy, by stopping treatment in molecular remission, appears to be feasible.

In this multi-centre open-label phase Ib-II trial the safety and efficacy of treatment of relapse/refractory Mantle Cell Lymfoma with Venetoclax, Lenalidomide and Rituximab was evaluated. In this MEDtalk Mats Jerkeman, MD, Ph.D., Department of Oncology, Lund University and Skane University Hospital,...

09/12/2020

ASH20 highlights: In this study John Gribben, Barts Cancer Institute, Queen Mary University of London, London, presents data from the first randomized Phase 3 study in CLL of a PI3Ki vs. chemo immunotherapy, and the first randomized study of a PI3Ki in treatment-naive CLL.

Highlights from ASH 2020: John Gribben presents a novel non-chemotherapy regimen, that is highly active in the treatment of CLL.

08/12/2020

ASH20 highlights: Ajai Chari, MD, Mount Sinai Medical Center, New York presents in this MEDtalk the initial results from an ongoing phase 1 dose escalation study of talquetamab. Talquetamab is a first-in-class bispecific antibody, that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through the recruitment and activation of T cells.

Highlights from ASH 2020: In this MEDtalk, MD. Ajai Chari presents the initial results from an ongoing phase 1 dose escalation study of talquetamab.

01/10/2020

In this MEDtalk M.D. Professor of Oncology, Julie Brahmer from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University presents data from KEYNOTE-024: Pembrolizumab double the 5-year OS rate for patients with metastatic, PD-L1-positive lung cancer vs chemotherapy.

27/09/2020

MEDtalk: Watch Professor of Medicine from Harvard Medical School Toni K. Choueiri, new first-line treatment option for metastatic kidney cancer. Log in watch the whole presentation: https://bpno.fi/2020/09/24/medtalk-new-first-line-treatment-option-for-metastatic-kidney-cancer/

24/09/2020

First new drug in years reduces recurrence in high-risk hormone receptor positive early breast cancer. Log in to watch the MEDtalk with Professor Stephen Johnston

31/08/2020

Lue uusin BestPractice Nordic -julkaisu digiversiona!

Pääkirjoitus.......................................................................................................7

26/06/2020

Käy lukemassa uusin COVID-19 update verkkosivuillamme. Tällä kertaa aiheena on COVID-19-virukseen liittyvät iho-oireet.

Up to 20% of COVID-19 cases have shown skin manifestations. Therefore, in trying to detect and manage the disease earlier and more effectively, it is important to understand how COVID-19 can appear on the skin.

08/06/2020

In this MEDtalk, Eric J. Small talks about to which extent patients with non-metastatic castration-resistant prostate cancer achieve metastasis-free survival and whether it is possible to delay the time until chemotherapy, as well as the impact of treatment on survival.